Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05320588 · ClinicalTrials.gov registry record · Phase 1
A Study in Patients With Advanced Cancers
A Phase 1 study of Cancer and Advanced Solid Tumor, sponsored by BiOneCure Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 332
- Enrollment target
- 3
- Study locations
NCT05320588: Recruiting Phase 1 study of Cancer and Advanced Solid Tumor, sponsored by BiOneCure Therapeutics.
NCT05320588 is a Phase 1 study of Cancer and Advanced Solid Tumor that is actively recruiting participants, run by BiOneCure Therapeutics. The registered enrollment target is 332 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (90% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05320588, a Phase 1 study of Cancer and Advanced Solid Tumor, is actively recruiting participants, sponsored by BiOneCure Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 332 participants
- Enrollment target
- 3
- Study locations
Study Summary
A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.
Primary Outcome
Escalation period
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG BIO-106
Study Locations (3)
Texas
- NEXT Oncology Austin - Austin
- University of Texas MD Anderson Cancer Center - Houston
Virginia
- NEXT Oncology Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2022-03-25 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
What NCT05320588 shows while recruiting
NCT05320588 is an interventional study that assigns participants to a tested intervention. The registered 332 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (90% lower).
The record links to 4 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05320588 reports a single indexed study location in Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT05320588 about?
NCT05320588 is a clinical study titled "A Study in Patients With Advanced Cancers". A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.
What is the current status of trial NCT05320588?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 332 participants. The study started on 2022-03-25. Estimated completion is 2027-04.
What conditions does trial NCT05320588 study?
This clinical trial studies the following conditions: Cancer, Advanced Solid Tumor, Advanced Cancer, Oncology.
What interventions are being tested in trial NCT05320588?
The interventions under investigation include: Pembrolizumab (DRUG), BIO-106 (DRUG).
Who is sponsoring clinical trial NCT05320588?
This trial is sponsored by BiOneCure Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05320588 being conducted?
This trial has 3 study locations across Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05320588's enrollment target sits among peer trials
332 171st of 615 higher than 445 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174121 · 332 participants · Phase 2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- NCT02605785 · 332 participants · NA
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
- NCT04894006 · 332 participants · NA
Dementia Family Caregiver Study
- NCT05130606 · 332 participants · NA
CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI